Verteporfin photodynamic therapy induced apoptosis in choroidal neovascular membranes

British Journal of Ophthalmology

Volumn 90, Issue 8, 2006, Pages 1034-1039

  Petermeier, K ^b   Tatar, O ^b   Inhoffen, W ^b   Volker M ^b   Lafaut, B A ^c   Henke Fahle, S ^b   Gelisken, F ^b   Ziemssen, F ^b   Bopp, S ^d   Bartz Schmidt, K U ^b   Grisanti, Salvatore ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c AZ StJan ^*  (Belgium)

^d UNIVERSITY OF BREMEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; CYTOKERATIN 18; ENDOGLIN; HEMATOXYLIN; KI 67 ANTIGEN;

ADULT; AGED; APOPTOSIS; CELL ACTIVATION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EYE SURGERY; FEMALE; HUMAN; IMMUNOHISTOLOGY; MAJOR CLINICAL STUDY; MALE; MICROPHOTOGRAPHY; NICK END LABELING; PHOTODYNAMIC THERAPY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA ANGIOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; REVIEW; STAINING; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; APOPTOSIS; CHOROIDAL NEOVASCULARIZATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IN SITU NICK-END LABELING; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RETROSPECTIVE STUDIES; VISUAL ACUITY;

EID: 33746534279     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.090852     Document Type: Review

References (21)

1. Ambati J, Ambati BK, Yoo SH, et al. Age-related macular degeneration: etiology, pathogenesis and therapeutic strategies. Surv Ophthalmol 2003;48:257-93.
2. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP Report 1. Arch Ophthalmol 1999;117:1329-45.
3. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidol neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP Report 2. Arch Ophthalmol 2001;119:198-207.
4. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP Report No 3. Arch Ophthalmol 2002;120:1443-54.
5. Verteporfin in Photodynamic Therapy Study group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 2001;131:541-60.
6. Blinder KJ, Bradley S, Bressler NM, et al. Treatment of Age-related Macular Degeneration with Photodynamic Therapy Study Group. Verteporfin in Photodynamic Therapy Study Group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP Report no 1. Am J Ophthalmol 2003;136:407-18.
7. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age related macular degeneration. Surv Ophthalmol 2000;45:195-214.
8. Schlötzer-Schrehardt U, Viestenz A, Naumann GOH, et al. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 2002;240:748-57.
9. Schnurrbusch UEK, Welt K, Horn L-C, et al. Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy. Br J Ophthalmol 2001;85:1086-91.
10. Ghazi NG, Jabbour NM, de la Cruz ZC, et al. Clinicopathologic studies of age-related macular degeneration with classic subfoveal choroidal neovascularization treated with photodynamic therapy. Retina 2001;21:478-86.
11. Gelisken F, Lafaut B, Inhoffen W, et al. Histopathologic findings of surgically excised choroidal neovascularization three days following photodynamic therapy in age-related macular degeneration. Br J Ophthalmol 2004;88:207-11.
12. Moshfeghi DM, Kaiser PK, Grossniklaus HE, et al. Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am J Ophthalmol 2003;135:343-50.
13. Arroyo JG, Michaud N, Jakobiec FA. Choroidal neovascular membranes treated with photodynamic therapy. Arch Ophthalmol 2003;121:898-903.
14. Grisanti S, Tatar O, Canbek S, et al. Immunohistopathologic evaluation of choroidal neovascular membranes following verteporfin-photodynamic therapy. Am J Ophthalmol 2004;137:914-23.
15. Tatar O, Kaiserling E, Adam A, et al. Consequences of werteprofin photodynamic therapy on choroidal neovascular membranes. Arch Ophthalmol (in press).
16. Schmidt-Erfurth U, Michels S, Barbazetto I, et al. Photodynamic effects on choroidal neovascularization and physiological choroids. Invest Ophthalmol Vis Sci 2002;43:830-41.
17. Hinton DR, He S, Lopez PF. Apoptosis in surgically excised choroidal neovascular membranes in age-related macular degeneration. Arch Ophthalmol 1998;116:203-9.
18. Wiezorrek R, Schäfer H, Bialasiewick AA, et al. Programmierter Zelltod (Apoptose) in exzidierten subretinalen Neovaskularisationen. Ophthalmologe 2000;97:79-83.
19. Dunaief JL, Dentchev T, Gui-Shuang Y, et al. The role of apoptosis in age-related macular degeneration. Arch Ophthalmol 2002;120:1435-42.
20. Schwartz LM, Ashwell JD. Methods in cell biology, Vol 66. Apoptosis. Academic Press, 2001.
21. Belzacq AS, Jacotot E, Vieira HLA, et al. Apoptosis induction by the photosensitizer verteporfin: identification of mitochondrial adenine nucleotide translocator as a critical target. Cancer Res 2001;61:1260-4.